Radiotherapy alone for stage I-III low grade follicular lymphoma: long-term outcome and comparison of extended field and total nodal irradiation by Guckenberger, Matthias et al.
Guckenberger et al. Radiation Oncology 2012, 7:103
http://www.ro-journal.com/content/7/1/103RESEARCH Open AccessRadiotherapy alone for stage I-III low grade
follicular lymphoma: long-term outcome
and comparison of extended field and total
nodal irradiation
Matthias Guckenberger*, Nikolaus Alexandrow and Michael FlentjeAbstract
Background: To analyze long-term results of radiotherapy alone for stage I-III low grade follicular lymphoma and to
compare outcome after extended field irradiation (EFI) and total nodal irradiation (TNI).
Methods and materials: Between 1982 and 2007, 107 patients were treated with radiotherapy alone for low grade
follicular lymphoma at Ann Arbor stage I (n = 50), II (n = 36) and III (n = 21); 48 and 59 patients were treated with EFI
and TNI, respectively. The median total dose in the first treatment series of the diaphragmatic side with larger
lymphoma burden was 38 Gy (25 Gy – 50 Gy) and after an interval of median 30 days, a total dose of 28 Gy
(12.6 Gy – 45 Gy) was given in the second treatment series completing TNI.
Results: After a median follow-up of 14 years for living patients, 10-years and 15-years overall survival (OS) were
64% and 50%, respectively. Survival was not significantly different between stages I, II and III. TNI and EFI resulted in
15-years OS of 65% and 34% but patients treated with TNI were younger, had better performance status and higher
stage of disease compared to patients treated with EFI. In multivariate analysis, only age at diagnosis (p< 0.001,
relative risk [RR] 1.06) and Karnofsky performance status (p = 0.04, RR = 0.96) were significantly correlated with OS.
Freedom from progression (FFP) was 58% and 56% after 10-years and 15-years, respectively. Recurrences outside
the irradiated volume were significantly reduced after TNI compared to EFI; however, increased rates of in-field
recurrences and extra-nodal out-of-field recurrence counterbalanced this effect resulting in no significant difference
in FFP between TNI and EFI. In univariate analysis, FFP was significantly improved in stage I compared to stage II
but no differences were observed between stages I/II and stage III. In multivariate analysis no patient or treatment
parameter was correlated with FFP. Acute toxicity was significantly increased after TNI compared to EFI with a trend
to increased late toxicity as well.
Conclusions: Radiotherapy alone for stage I and II follicular lymphoma resulted in long-term OS with high rates of
disease control; no benefit of TNI over EFI was observed. For stage III follicular lymphoma, TNI achieved promising
OS and FFP and should be considered as a potentially curative treatment option.
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Follicular lymphoma (FL) is after diffuse large B-cell
lymphoma the second most common subtype of non-
Hodgkin’s lymphomas in adults (~ 20–25%). Radiother-
apy alone is an established curative treatment option for
patients with stage I-II FL [1-3]. However, the volume,
which needs to be irradiated, is still an issue of contro-
versy. As the site of treatment failure is most frequently
nodal outside irradiated involved volumes, extended-
field irradiation (EFI) or even total nodal irradiation
(TNI) have been proposed to improve outcome com-
pared to involved-field irradiation (IFI). While studies
reported improved progression free survival (PFS) after
treatment of larger volumes, this did not transfer into
improved overall survival (OS) [4,5]. Despite the major-
ity of relapses are observed within 5 years after radio-
therapy, late recurrences 15 – 20 years after treatment
[4-6] indicate the need for studies with long-term
follow-up, which are scarce in the literature.
Stage III disease is considered as non-curative and
chemotherapy or wait and see strategies are most fre-
quently perused. Nevertheless, studies reported promis-
ing disease control and overall survival rates after
radiotherapy alone for stage III FL [7,8]. Recent data
reported that lower radiation doses are sufficient for dis-
ease control [9], which might further reduce acute and
especially long term toxicity. In this context of poten-
tially reduced toxicity, radiotherapy in form of TNI
might become a more attractive treatment strategy for
advanced stage of disease. It was consequently the aim
of this retrospective single institution study to describe
long-term outcome after radiotherapy alone for stage I-
III FL and to compare patterns of failure and OS after
EFI and TNI.
Material and methods
Between 1982 and 2007, 107 patients were treated with
radiotherapy alone for low grade follicular lymphoma.
Of these 107 patients, Ann Arbor stage was I (n = 50), II
(n = 36) and III (n = 21). Ann Arbor stage was based on
contrast enhanced whole body CT imaging and bone
marrow biopsy in all patients.
All patients were treated with radiotherapy alone as
primary treatment; patients who received chemotherapy
as part of the primary treatment were excluded from
this analysis. Patients were treated with either EFI
of all central lymph node regions on the involved
side of the diaphragm (supra-diaphragmatic: cervical,
supra- and infraclavicular, mediastinal and hilar; infra-
diaphragmatic: paraaortal, iliacal, inguinal) or with TNI
(sequential supra-diaphragmatic and infra-diaphragmatic
irradiation). Treatment was always started at the dia-
phragmatic side with higher lymphoma burden (first
series) followed by the side with lower lymphomaburden or elective irradiation (second series). Total
lymphatic irradiation with routine treatment of the Wal-
deyer’s tonsillar ring and mesenteric lymph nodes was
not practiced. The spleen and Waldeyer's tonsillar ring
were irradiated in 12% and 36% of the patients, respect-
ively. Single fraction doses ranged between 1.5 Gy
−2.0 Gy with the majority of patients treated with 1.8 Gy
or 2.0 Gy. Lymph node regions without macroscopic in-
volvement were treated with a total dose of 30 Gy and a
boost of 6 - 8 Gy was given to macroscopic involved
lymph node regions: the median total dose in the first
treatment series was 38 Gy (25 Gy – 50 Gy) and after a
median interval of 30 days, a total dose of 28 Gy
(12.6 Gy – 45 Gy) was given in the second treatment
series.Statistical analysis
Patient and treatment characteristics were compared be-
tween the two groups treated with EFI and TNI and be-
tween stage I/II and stage III using Chi-squared test for
categorical variables and Mann-Withney U-test for con-
tinuous variables using Statistica X software (Statsoft,
Tulsa, OK, USA). Survival and recurrence data were cal-
culated by the Kaplan–Meier method: overall survival
(OS) and freedom from progression (FFP) were calcu-
lated. Results between subgroups were compared using
the log-rank test and the influence of patient and treat-
ment factors on OS and FFP was evaluated using the
multivariate Cox proportional-hazards regression model
with backward exclusion of non-significant variables.
Results with p< 0.05 were considered as statistically
significant.Results
Patient characteristics and involved lymph node regions
are summarized in Tables 1 and 2. Differences between
EFI and TNI reflect the decision making process for the
two approaches. Younger patients with better perform-
ance status were treated predominantly with TNI. Pres-
ence of B-symptoms, elevated serum LDH and bulky
disease were not different between ENI and TNI. Add-
itionally, no differences in total irradiation doses were
observed.
The median number of involved lymph node regions
was 2 (range 2–5) and 4 (range 2–11) in stage II and III
disease, respectively. Patients at stage III were younger
compared to stage I/II and elevated LDH was observed
more frequently in stage III patients; there were no dif-
ference in the rate of bulky disease and irradiation doses.
Of patients with stage III disease, 18/21 were treated
with TNI; one patient denied infra-diaphragmatic after
supra-diaphragmatic irradiation and the reason for two
patients is unknown.
Table 1 Patient and treatment characteristics with comparison between EFI and TNI and between stages I/II and stage
III disease
All EFI TNI p-value Stage I/II Stage III p-value
# patients 107 48 59 86 21
Age <0.001 <0.001
median/range [years] 57 26 - 83 66 37 - 83 51 26 - 74 61 27 – 83 51 26 - 68
≥60 years 48 45% 35 73% 13 22% 45 52% 3 14%
Sex [male] 59 57% 26 55% 33 56% NS 49 57% 10 48%
Karnofsky Performance status <0.001 NS
median/range 90 50 - 100 90 50 - 100 100 80 - 100 90 50 – 100 90 70 – 100
B-Symptoms 1 1% 0 0% 1 2% NS 0 0% 1 5% NS
LDH NS 0.03
Elevated 16 15% 9 19% 7 12% 8 9% 8 38%
Normal 63 59% 29 60% 34 58% 55 64% 8 24%
unknown 28 26% 10 21% 18 30% 23 27% 5 38%
Ann Arbor stage 0.04
I 50 47% 27 56% 23 39.0%
II 36 34% 18 38% 18 30.5%
III 21 20% 3 6% 18 30.5%
Bulk ≥7.5 cm 5 5% 2 4% 3 5% NS 3 3% 2 9% NS
Radiotherapy dose median/range [Gy] 38 25 - 50 38 27 - 50 37 25 - 46 NS 37 25 - 50 37 29 - 46 NS
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26 years) and 14 years (2–26 years) for living patients.
Follow-up was not different between EFI and TNI and
between stages I/II and stage III.
For the total patient population, 10-years and 15-years
OS were 64% and 50% (Figure 1), respectively. In uni-
variate analysis, age>median of 60 years (p = 0.0001),
EFI versus TNI (p = 0.001) and Karnofsky performance
status <100 (p = 0.0003) were correlated with decreased
OS. Median age of 60 years differentiated between 15-
years OS of 67% and 29%; TNI and EFI resulted in 15-
years OS of 65% and 34% (Figure 2a), respectively.
Overall survival was not significantly different between
stages I-III: 15-years OS were 51%, 45% and 54% for
patients with stage I, II and III (Figure 2b), respectively.
In Cox proportional-hazards analysis (with age, TNI vs
ENI, Karnofsky performance status and Ann Arbor stage
included into the modelling), age at diagnosis (p< 0.001
and relative risk of 1.06) and Karnofsky performance sta-
tus (p = 0.04 and relative risk of 0.96) were significantly
correlated with OS (Table 3).Table 2 Distribution of involved lymph node regions separate
lymphoma
Neck Axilla Mediastinum
Stage I (n = 50) 46% 8% 0%
Stage II (n = 36) 81% 39% 31%
Stag III (n = 21) 76% 62% 24%FFP was 76%, 58% and 56% after 5-years, 10-years and
15-years (Figure 1), respectively. Only one recurrence
was observed after 10 year (12.8 years). FFP at 10 years
was not different between TNI and EFI with 62% and
54% (p = 0.50) (Figure 3a), respectively. FFP at 10 years
was 74%, 40% and 62% for stage I, stage II and stage III
(Figure 3b), respectively, and results of stage II were
significantly worse compared to stage I (p = 0.001). In
Cox proportional-hazards analysis (with Ann Arbor
stage, age and TNI vs ENI included into the modelling),
no patient or treatment characteristic was correlated
with FFP.
A total of 35 recurrences were observed with crude
rates of 33% and 32% after EFI and TNI, respectively.
14/16 (87.5%) and 8/19 (42%) of the recurrences after
EFI and TNI were located outside the irradiated volume,
which was highly significant (p = 0.01).
During the first irradiation series, 5 patients (5%)
developed acute toxicity grade III (gastrointestinal
mucositis n = 4; nausea and vomiting n = 1). During the
second irradiation series in TNI patients, acute toxicityly for patients with stage I, stage II and stage III follicular
Paraaortal Iliakal Inguinal Unknown
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Figure 1 Kaplan Meier Curves showing overall survival (OS) and freedom from disease progression (FFP) for all patients.
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ing grade IV toxicity (thrombocytopenia) and 8 patients
(14%) suffering from grade III toxicity (leukopenia n = 3,
thrombocytopenia n = 2, gastrointestinal mucositis n = 2,
nausea and vomiting n = 1).
Late toxicity was maximum grade II in all patients and
grade II toxicity was observed in 27 patients (25%). The
most frequent grade II toxicity was pulmonary (n = 12;
pulmonary fibrosis, dyspnoea, cough) and gastro-
intestinal (n = 9; dry mouth, dysphagia, dental, hepatitis,
colitis). Two patients developed chronic haematological
toxicity and one patient generalized dry skin and fatigue.
Any grade II toxicity was increased after TNI (n = 18;
31%) compared to EFI (n = 8; 17%) but this difference
did not reach statistical significance.
Discussion
This study confirms previous data, that treatment of lar-
ger irradiation fields does not improve overall survival in
stage I and II follicular lymphoma. Wilder et al. reported
the M.D. Anderson experience of 80 patients treated
with IFI (9%), regional RT (54%; treatment of 1–3 adja-
cent, grossly uninvolved nodal regions) or EFI (37%);
TNI irradiation was not practiced [5]. After a median
follow-up of 19 years for living patients, no difference in
OS was observed between EFI and IFI/regional RT: 49%
versus 40% at 15 years. Recurrences were more fre-
quently observed in patients treated with EFI; however,
there were imbalances of stage distribution and total ir-
radiation dose and no multivariate analysis was per-
formed. Mac Manus et al. described the Stanford
experience of 177 patients and differentiated betweenirradiation of the involved side or both sides of the dia-
phragm [4]. After a median follow-up of 7.7 years, FFP
at 10 year were 36% and 67% for treatment of the
involved side only and both sides of the diaphragm, re-
spectively, which was highly significant. However, this
improvement in disease control did not transfer into
increased OS.
In our own study, evaluating the impact of TNI and
EFI on FFP and OS was difficult because of a correlation
between the target volume concept and established
prognostic parameters: age of the patients, performance
status and stage of disease. No difference of FFP was
observed between TNI and EFI in univariate and multi-
variate analysis. In agreement to Stuschke et al. [10],
irradiation of uninvolved lymph node regions with a
median dose of 30 Gy was effective in reducing out-of-
field recurrences. However, an increased rate of in-field
recurrences and extra-nodal out-of-field recurrence
counterbalanced this beneficial effect of TNI. Regarding
OS, patients treated with TNI were younger and had a
better performance status and as a consequence, 15-years
OS was 65% and 34% after TNI and EFI, respectively.
However, only age and Karnofsky performance status
and not the target volume concept remained statistically
significant in multivariate analysis.
The 10-years OS of 64% for the patient population
with stages I/II disease is considered as representative
for early stage follicular lymphoma because our depart-
ment is the only radiotherapy centre within a radius of
minimum 50 – 100 km and rather strict referral patters
in the geographical region; a potential patient selection
bias is consequently limited. The observed OS is in good
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Figure 2 Kaplan Meier Curves showing overall survival in relationship to TNI versus EFI (no significant difference) (Figure 2a) and stage
of disease (no significant differences) (Figure 2b).
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primary radiotherapy for stages I/II follicular lymphoma:
two recent literature reviews reported 10-years OS rates
ranging between 46% and 79% (weighted average of 63%
in Heinzelmann et al.) after primary radiotherapy using
mostly IFI or EFI [11,12]. No obvious correlation of OS
and irradiated volume is seen in this literature review.
This further supports the hypothesis of no OS benefit
after TNI.
The larger treatment volumes of TNI came at the
price of increased toxicity. While the first series of EFIirradiation was well tolerated with only 5% of the
patients developing grade III toxicity, 16% of the patients
suffered from acute toxicity grade ≥ III during the second
series, which completed the TNI. Additionally, chronic
toxicity grade II was observed more frequently after TNI
(31%) compared to EFI (17%).
Randomized data about the question of the appropri-
ate irradiation volume are missing. A German multicen-
tre phase III trial, which randomized between TNI and
EFI, closed in 2007 and final results are awaited. Until
results of this trial are available, increased acute and
Table 3 Univariate and multivariate analysis of patient and treatment factors influencing overall survival and freedom
from disease progression
Overall Survival Freedom from disease progression
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
Age p= 0.0001 p = 0.0001 RR= 1.06 NS
Karnofsky performance status p= 0.0003 P = 0.04 RR = 0.96 NS
Stage of disease NS P= 0.001 NS NS
TNI vs EFI p= 0.001 NS NS
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Figure 3 Kaplan Meier Curves showing freedom from disease progression in relationship to TNI versus EFI (no significant difference)
(Figure 2a) and stage of disease (significant difference between stage I and stage II) (Figure 2b).
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survival and disease control as observed in this study do
not support the concept of TNI compared to EFI for
stage I and II FL.
Twenty one patients with stage III FL were treated
with radiotherapy alone and were included into this
study. Unfortunately, prognostic factors were not fully
balanced between stages I/II and stage III. Patients at
stage III FL were younger indicating that age was a se-
lection criterion for radiotherapy alone in stage III
patients. As expected based on the increased lymphoma
burden, LDH was more frequently elevated in stage III
patients. TNI was the planned treatment in all stage III
patients and was successfully completed in almost 90%
of the patients.
Outcome was favourable with 10-years OS and FFP of
61% and 62%, respectively. OS and FFP were not signifi-
cantly different to stages I/II. This favourable outcome is
in good agreement with data in the literature [7,8,13,14],
where 10-years OS ranged between 47% and 65%. Only
a small number of patients with stage III disease was at
risk after 10 years in our study; however, the Stanford
experience of 66 stage III patients treated with radio-
therapy alone described no disease recurrence after
10 years and only 5/29 lymphoma deaths after 10 years
[8]. These data are promising especially in the light of
the recently published British trial, which showed that
radiotherapy doses for indolent lymphomas can be
reduced without negatively affecting clinical outcome.
Consequently, TNI with reduced irradiation may have
the potential of long term disease control and survival
with simultaneously decreased acute and chronic toxicity
[9]. Of course, such concepts need to be validated within
clinical trials.
Some limitations of our study need to be discussed.
The retrospective nature of this study is associated with
well-known limitations. The decision making process be-
tween EFI and TNI considered well established prognos-
tic factors like age, performance status and stage of FL,
which made the statistical comparison of the two target
volume concepts difficult. Additionally, the reconstruc-
tion of the decision making process in favour of radio-
therapy and against chemotherapy in stage III FL could
not be fully reconstructed: the ratio of stage I + II : stage
III patients in the International Lymphoma classification
project was 2:1 [15] compared to 4:1 in our study, which
suggests some selection process for radiotherapy.
Conclusions
Radiotherapy alone for stage I and II follicular lymph-
oma was an effective and curative treatment with high
rates of disease control. Larger irradiation fields covering
both sides of the diaphragm did not improve tumor
control and overall survival. Additionally, TNI wasassociated with increased rates of acute and chronic tox-
icity. Based on this study and data from the literature,
EFI or IFI are the preferred treatments for stage I and II
follicular lymphoma. In patients with stage III FL, TNI
resulted in promising tumor control and overall survival
and should be considered as a potentially curative treat-
ment option.
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